检测矽肺患者的抗拓扑异构酶 I 自身抗体。
Detection of anti-topoisomerase I autoantibody in patients with silicosis.
机构信息
Department of Hygiene, Kawasaki Medical School, 577 Matsushima, 701-0192, Kurashiki, Okayama, Japan,
出版信息
Environ Health Prev Med. 2002 Apr;7(1):7-10. doi: 10.1007/BF02898059.
OBJECTIVES
The aim of this study was to detect anti-topoisomerase I (anti-topo I) autoantibodies, which are known to be limited in systemic sclerosis patients, in silicosis patients with no clinical symptoms of autoimmune disease.
METHODS
Serum anti-topo I autoantibodies were detected using ELISA. Differences in clinical parameters between patients with and without anti-topo I autoantibodies were analyzed.
RESULTS
Seven of 69 patients had anti-topo I autoantibodies. These 7 patients showed elevated PaCO(2) values (P=0.0212), and inverse correlations between serum soluble Fas levels and PaCO(2) values were found.
CONCLUSION
Anti-topo I autoantibodies were detected in 10.1% of silicosis patients without any clinical symptoms of autoimmune disease. The findings here suggest that the genesis of anti-topo I autoantibodies might be related to pulmonary involvement or lung fibrosis associated with progression of silicosis.
目的
本研究旨在检测系统性硬化症患者中有限的抗拓扑异构酶 I（抗拓扑 I）自身抗体，在无自身免疫性疾病临床症状的矽肺患者中。
方法
采用 ELISA 法检测血清抗拓扑 I 自身抗体。分析有和无抗拓扑 I 自身抗体的患者之间临床参数的差异。
结果
69 例患者中有 7 例存在抗拓扑 I 自身抗体。这 7 例患者的 PaCO2 值升高（P=0.0212），并且发现血清可溶性 Fas 水平与 PaCO2 值之间存在负相关。
结论
在无任何自身免疫性疾病临床症状的矽肺患者中检测到抗拓扑 I 自身抗体。这些发现表明，抗拓扑 I 自身抗体的产生可能与矽肺进展相关的肺部受累或肺纤维化有关。
Zotero 插件